A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1972 in HIV-1 Infected Patients

Trial Profile

A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1972 in HIV-1 Infected Patients

Discontinued
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs MK 1972 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 04 Feb 2016 Frequency of dosage (50-800 mg/day) changed from BID to OD in part 1 and 50-100 mg/day BID in part 1 as per ClinicalTrials.gov record.
    • 26 Jan 2012 Actual patient number (12) added as reported by ClinicalTrials.gov.
    • 26 Jan 2012 Planned End Date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top